CoolSculpting is Now FDA Approved to Improve Lax Tissue in Double Chin

Tuesday, December 12, 2017 | FDA Approval/Clearance , Allergan


The FDA has approved CoolSculpting treatment for the improved appearance of lax tissue in conjunction with submental fat, or double chin, treatments.  Allergan's CoolSculpting for the double chin is already clinically proven to reduce fat up to 20 percent in the treated area after one treatment.

"In my own patients, I have noticed the improved appearance of lax tissue when using the CoolMini applicator for the CoolSculpting system to treat the submental area," said Jeffrey S. Dover, MD, FRCPC, Co-Director of SkinCare Physicians of Chestnut Hill, Mass. "It is great to see the company invest to validate this and secure the FDA clearance."

An 18-week clinical study of CoolSculpting in submental fat treatment found that 77 percent of patients showed improved appearance of lax tissue and 75 percent of patients reported their chin looked more toned following treatment.

"Allergan is committed to advancing innovation for CoolSculpting to meet the needs of patients seeking non-invasive aesthetic treatments," said David Nicholson, Chief Research and Development Officer at Allergan. "A 2017 American Society for Dermatologic Surgery (ASDS) survey revealed that 73 percent of patients are bothered by excess fat under the chin. We are pleased this patient concern can successfully be addressed by CoolSculpting through a non-invasive approach, and furthermore improve the appearance of lax tissue in the treated area."

Next Story

Comments

You must be logged in to leave a comment.